首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1935339

结核病药物市场按治疗方法、疾病类型、分销管道和地区划分

Tuberculosis Drugs Market, By Therapy Type, By Disease type, By End User , By Geography

出版日期: 2026年01月19日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计到 2026 年，结核病治疗药物市场价值将达到 25.1 亿美元，预计到 2033 年将达到 34.9 亿美元，2026 年至 2033 年的复合年增长率为 4.77%。

报告覆盖范围		报告详情
基准年：	2025	2026年市场规模：	25.1亿美元
历史数据时期：	2020年至2024年	预测期：	2026年至2033年
预测期（2026-2033年）复合年增长率：	4.77%	2033 年的预测值：	34.9亿美元

结核病是由结核分枝桿菌引起的常见感染疾病，主要侵犯肺部。结核病的治疗分为第一线治疗和二线治疗。第一线治疗包括使用异烟肼（INH）、利福平（RIF）、Pyrazinamide（PZA）、乙胺丁醇（EMB）和链霉素（SM）等药物。然而，第一线治疗对抗药性结核病往往无效。结核病又分为潜伏期结核病和活动期结核病。

结核病的高发生率正在推动这一市场的成长。例如，根据世界卫生组织统计，2017年新增结核病病例中，有87%发生在结核病高发生的30个国家。在这30个国家中，印度、中国、印尼、菲律宾、巴基斯坦、奈及利亚、孟加拉和南非这8个国家的新增结核病病例占总数的2/3。

市场动态

全球结核病负担日益加重，预计将推动结核病治疗市场成长。例如，根据美国疾病管制与预防中心（CDC）的数据，2017年全球共有1,000万例结核病病例，130万人死于结核病。

此外，根据世界卫生组织2018年发布的数据，结核病每年造成全球整体210亿美元的损失，其中92亿美元用于治疗和预防，120亿美元用于其他经济损失和生产力损失。预计医疗保健领域结核病治疗医疗费用支出的增加将推动市场成长。此外，据世界卫生组织称，多重抗药性结核病（MDR-TB）的治疗週期为20至26个月，在美国的平均治疗费用约为29.4万美元。

此外，加大研发投入预计将推动市场成长。根据《2005-2017年结核病研究经费趋势》报告，2017年全球结核病研究投资额为7.72亿美元，较2016年的7.26亿美元成长6%（4,600万美元）。

本研究的主要特点：

本报告以 2025 年为基准年，对结核病治疗市场规模（十亿美元）和预测期（2026-2033 年）的复合年增长率进行了详细分析。
它重点介绍了各个细分市场的潜在商机，并说明了该市场具有吸引力的投资提案矩阵。
该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
该报告根据公司概况、财务表现、产品系列、地理覆盖范围、关键发展和策略等参数，对全球结核病药物市场的主要企业进行了概况介绍。
本报告的研究结果将使企业负责人和经营团队能够就产品发布、政府倡议、市场扩张和行销策略做出明智的决策。
这份全球结核病治疗市场报告的目标受众是业内各种相关人员，包括投资者、产品製造商、经销商、结核病治疗供应商、研究和咨询公司、新参与企业和金融分析师。

北美洲
- 我们
- 加拿大
欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲
亚太地区
- 中国
- 日本
- 印度
- ASEAN
- 澳洲
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲国家
非洲
- 北非
- 中非
- 南非
中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家

第八章竞争情势

公司简介
- Lupin ltd.
- Johnson &Johnson Services, LLC
- Novartis AG
- Macleods Pharmaceuticals Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer Inc.

第九章各节

参考
调查方法

简介目录

Product Code: CMI191

Tuberculosis Drugs Market is estimated to be valued at USD 2.51 Bn in 2026 and is expected to reach USD 3.49 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.77% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2.51 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.77%	2033 Value Projection:	USD 3.49 Bn

Tuberculosis is a common infectious disease caused by mycobacterium tuberculosis that affects the lungs. The treatment of TB is divided into two types; first line therapy and second line therapy. In first line therapy, TB is treated with drugs such as isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), ethambutol (EMB), and streptomycin (SM). However, first line therapy fails more often in the cases of drug resistant bacterial TB. Tuberculosis is classified into latent tuberculosis and active tuberculosis.

The high burden of TB is driving the growth of this market. For instance, according to the WHO, in 2017, 87% of new TB cases occurred in 30 high TB burden countries. The eight countries out of 30 include India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa which accounted for two thirds of the new TB cases.

Market Dynamics

Increasing global burden of TB is expected to drive the tuberculosis drugs market growth. For instance, according to the Centre for Disease Control and Prevention, in 2017, 10.0 million people around the world suffered from TB, and there were 1.3 million TB-related deaths worldwide.

Moreover, according to WHO data published in 2018, TB costs the world over US$ 21 billion each year, including US$ 9.2 billion for treatment and prevention, and US$12 billion in additional economic costs and lost productivity. Increasing healthcare spending on treatment of TB is expected to drive growth of the market. Moreover, according to the WHO, treatment for multi-drug resistant TB (MDR-TB) takes 20-26 months, and average cost of treatment in the U.S. is around US$ 294,000.

Moreover, increasing investments in research and development activities are expected to drive growth of the market. According to the Tuberculosis Research Funding Trends 2005-2017 reports, global investment in TB research was valued at US$ 772 Million in 2017 with an increase of 6% (or US$ 46 million), compared to US$726 million in 2016.

Key features of the study:

This report provides in-depth analysis of the market, tuberculosis drugs market size (USD Bn), and compound annual growth rate (CAGR%) for the forecast period (2026 - 2033), considering 2025 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global tuberculosis drugs market based on the following parameters such as company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study include, include Johnson & Johnson Services, LLC, Lupin Ltd, Novartis AG, Macleods Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., and others.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to product launches, governmental initiatives, market expansion, and marketing tactics
The global tuberculosis drugs market report caters to various stakeholders in this industry such as investors, product manufacturers, distributors, and suppliers of TB drugs, research and consulting firms, new entrants, and financial analysts

Market Segmentation

By Therapy Type,
- First Line Therapy
- Isoniazid (INH)
- rifampicin (RIF)
- Ethambutol (EMB)
- Pyrazinamide (PZA)
- Streptomycin (SM).
- Second Line Therapy
- Fluoroquinolones
- Injectable antituberculosis drugs
By Disease Type,
- Active TB
- Latent TB
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Tuberculosis Drugs Market - Competitive Landscape
- Johnson & Johnson Services, LLC
- Lupin Ltd
- Novartis AG
- Macleods Pharmaceuticals Ltd.
- Otsuka Pharmaceutical Co., Ltd
- Pfizer Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Disease Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Landscape
Drug Recall
Porter's Five Forces Model

4. Global Tuberculosis Drugs Market, By Therapy Type, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2017 - 2033
- Segment Trends
First Line Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Bn)
  - Isoniazid (INH)
  - rifampicin (RIF)
  - Ethambutol (EMB)
  - Pyrazinamide (PZA)
  - Streptomycin (SM)
Second Line Therapy
- Fluoroquinolones
- Injectable antituberculosis drugs

5. Global Tuberculosis Drugs Market, By Disease Type, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2017 - 2033
- Segment Trends
Active TB
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Bn)
Latent TB
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Bn)

6. Global Tuberculosis Drugs Market, By Distribution Channel, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2017 - 2033
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Bn)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Bn)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Bn)

7. Global Tuberculosis Drugs Market, By Region, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2018- 2033
- Regional Trends
North America
- Market Size and Forecast, By Therapy Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Bn)
  - U.S.
  - Canada
Europe
- Market Size and Forecast, By Therapy Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Therapy Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Bn)
  - China
  - Japan
  - India
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Market Size and Forecast, By Therapy Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Africa
- Market Size and Forecast, By Therapy Type 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Country/Region, 2026 - 2033, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa
Middle East
- Market Size and Forecast, By Therapy Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East

8. Competitive Landscape

Company Profiles
- Lupin ltd.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Johnson & Johnson Services, LLC
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Macleods Pharmaceuticals Ltd.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Otsuka Pharmaceutical Co., Ltd.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
  - Analyst Views

9. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

结核病药物市场按治疗方法、疾病类型、分销管道和地区划分